Role of transcription factors in the action of antipsychotic drugs
Role of transcription factors in the action of antipsychotic drugs
批准号:
7589422
负责人:
Samuel Newton Sathyanesan
金额:
$17.69万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-15 至 2011-04-30
关键词:
AcidsAdverse effectsAffinityAntipsychotic AgentsAutoradiographyBehaviorBehavioralBehavioral GeneticsBindingBrainBrain regionCellsChronicCorpus striatum structureDNA-Binding ProteinsDataDrug effect disorderElementsEmulsionsEnhancersExhibitsFamilyGene ExpressionGene TargetingGenesGenetic ModelsGenomicsGoalsGrantGrowthHaloperidolHybridization ArrayImmunohistochemistryImpaired cognitionIn Situ HybridizationKnowledgeLeadLifeMeasuresMediatingMolecularNeuronal PlasticityNeuronsNuclear ReceptorsNucleic Acid Regulatory SequencesPatientsPatternPharmaceutical PreparationsPhenotypePlayPrefrontal CortexPromoter RegionsPsychotic DisordersRXRRattusReportingResearchRetinoic Acid ReceptorRetinoidsRoleSchizophreniaSlideStimulusSuicideSymptomsSynapsesTestingTherapeutic EffectValidationWorkatypical antipsychoticbasechromatin immunoprecipitationdesigndrug administration durationfrontal lobehigh riskimprovedinsightinterestolanzapineprogramspromoterpublic health relevancereceptorresponsetranscription factorziprasidone
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Role of Transcription factors in the action of Antipsychotic Drugs Schizophrenia is a major psychotic disorder that frequently has devastating effects on various aspects of the patient's life and carries a high risk of suicide and other life-threatening behaviors. Conventional, typical antipsychotics such as haloperidol are useful in treating the symptoms but do not improve cognitive impairment and exhibit undesirable side effects. Alternately, atypical antipsychotics, olanzapine and ziprasidone have been shown to have superior efficacy on cognitive impairments, fewer extrapyramidal side effects and a broader range of therapeutic effects. The precise molecular mechanisms governing the effects of antipsychotics are not well understood. We hypothesize that the antipsychotic action is via neuroplasticity and synaptic remodeling due to changes in gene expression. Earlier work from multiple research groups have shown robust alterations in gene expression of the Fos, Egr, retinoid acid nuclear receptor and Nurr family of transcription factors (TFs) in response to APD administration. Typical and atypical APDs also exhibit differences in brain sub-region induction patterns of these TFs. Although the induction of TFs by APDs has been investigated for over a decade, very little is known about the functional activity of these TFs and the downstream gene targets that they modulate. The fact that different classes of APDs differentially modulate TF expression based on brain region and duration of drug administration indicates that TFs could play an important role in the mechanism of APD action. The aim of this R21 Exploratory grant is to characterize transcription factor functional activation by employing a combination of chromatin immunoprecipitation (ChIP) and promoter arrays. TF functional activity will be characterized in the prefrontal cortex and striatum, two well characterized brain regions implicated in schizophrenia as well as APD action. The neuronal phenotype of TF-induced cells will be determined by a combination of immunohistochemical and in situ hybridization analysis. This study will enhance our understanding of the role played by transcription factors in mediating APD action and gene expression. The results from these studies should lead to an RO1 proposal aimed at extending these findings by manipulating specific TFs and investigating their influence in behavioral and genetic models. PUBLIC HEALTH RELEVANCE: The molecular mechanism of antipsychotic drug action is not well understood. Several studies have reported the brain region specific induction of DNA-binding proteins (transcription factors, TF) by these drugs. The functional activity of these transcription factors using microarray chips.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of trophic factor induced antidepressant action
-
批准号:9222795
-
项目类别:
-
资助金额:$35.93万
-
财政年份:2016
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
Trophic Factors in Cognition
-
批准号:10296124
-
项目类别:
-
资助金额:$37.27万
-
财政年份:2016
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
Trophic Factors in Cognition
-
批准号:10491246
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2016
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
Trophic Factors in Cognition
-
批准号:10685440
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2016
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
Role of transcription factors in the action of antipsychotic drugs
-
批准号:7842630
-
项目类别:
-
资助金额:$21.23万
-
财政年份:2009
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
Choroid plexus & antidepressants: genomics & proteomics
-
批准号:7100379
-
项目类别:
-
资助金额:$15.33万
-
财政年份:2006
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
Choroid plexus & antidepressants: genomics & proteomics
-
批准号:7282727
-
项目类别:
-
资助金额:$17.89万
-
财政年份:2006
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
GENE-EXPRESSION CHANGE AND ANTI-DEPRESSANT RESPONSE
-
批准号:6672348
-
项目类别:
-
资助金额:$13.71万
-
财政年份:2003
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
GENE-EXPRESSION CHANGE IN HUMAN BLOOD SAMPLES AND ANTI-DEPRESSANT RESPONSE
-
批准号:6765143
-
项目类别:
-
资助金额:$13.82万
-
财政年份:2003
-
负责人:Samuel Newton Sathyanesan
-
依托单位:
海外基金